Nabriva Therapeutics (NBRV) Earns Buy Rating from Analysts at Bank of America

Bank of America initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the biotechnology company’s stock.

NBRV has been the subject of several other reports. Wedbush reiterated an outperform rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th. Zacks Investment Research lowered shares of Nabriva Therapeutics from a hold rating to a sell rating in a research report on Wednesday. ValuEngine lowered shares of Nabriva Therapeutics from a sell rating to a strong sell rating in a research report on Friday, February 2nd. Morgan Stanley began coverage on shares of Nabriva Therapeutics in a research report on Wednesday, January 17th. They issued an overweight rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics and gave the stock a buy rating in a research report on Friday, March 16th. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $16.69.

How to Become a New Pot Stock Millionaire

NBRV stock opened at $5.51 on Wednesday. Nabriva Therapeutics has a 1 year low of $4.75 and a 1 year high of $14.10.

A number of hedge funds and other institutional investors have recently bought and sold shares of NBRV. Millennium Management LLC purchased a new stake in Nabriva Therapeutics during the fourth quarter valued at about $5,188,000. Alyeska Investment Group L.P. purchased a new stake in Nabriva Therapeutics during the third quarter valued at about $5,724,000. Prosight Management LP purchased a new stake in Nabriva Therapeutics during the fourth quarter valued at about $2,939,000. Pura Vida Investments LLC purchased a new stake in Nabriva Therapeutics during the third quarter valued at about $3,481,000. Finally, Rubric Capital Management LP purchased a new stake in Nabriva Therapeutics during the third quarter valued at about $2,457,000. Institutional investors and hedge funds own 55.59% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nabriva Therapeutics (NBRV) Earns Buy Rating from Analysts at Bank of America” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3296667/nabriva-therapeutics-nbrv-earns-buy-rating-from-analysts-at-bank-of-america.html.

About Nabriva Therapeutics

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ride My Car  Trading Up 136% This Week
Ride My Car Trading Up 136% This Week
Creditbit Trading Up 4.4% This Week
Creditbit Trading Up 4.4% This Week
Park-Ohio Holdings Corp.  Given Average Recommendation of “Hold” by Brokerages
Park-Ohio Holdings Corp. Given Average Recommendation of “Hold” by Brokerages
Contrasting resTORbio  and BioLineRx
Contrasting resTORbio and BioLineRx
Contrasting MarineMax  & U.S. Auto Parts
Contrasting MarineMax & U.S. Auto Parts
Target  and Its Rivals Critical Review
Target and Its Rivals Critical Review


© 2006-2018 Ticker Report. Google+.